SARCLISA is the first and only treatment to be approved based on a large Phase 3 study when given together with Pomalyst® (pomalidomide) and dexamethasone (Pd)
SARCLISA was studied when given together with Pd and compared to Pd alone. 307 people with relapsed refractory multiple myeloma took part in the study. 154 people received SARCLISA + Pd and 153 people received Pd alone.
People in the study had at least 2 prior treatments for multiple myeloma, including Revlimid® (lenalidomide) and a proteasome inhibitor (PI).
The goals of the SARCLISA study
The main goal of the SARCLISA study was to measure the amount of time a person lives with multiple myeloma without it getting worse. This is commonly referred to as progression-free survival
Another goal of the study was to measure how many people responded positively to treatment. A positive response to treatment means a decrease in the number of myeloma cells in the bone marrow.
Response to treatment is determined by tests performed after treatment has begun
You are unique — and so is your Multiple Myeloma
SARCLISA was studied in a wide variety of people with relapsed refractory Multiple Myeloma
About people in the SARCLISA study
Ages ranged from
36 to 86 years old
173 people had previously received
stem cell transplant for their multiple myeloma
and 134 had not
More than 90% of people had
previously stopped responding
to treatment with Revlimid®
Some people in the study had other medical
conditions in addition to relapsed refractory multiple myeloma